Argenx
ARGX
$368.60
Share price
-1.71%
Change (1 day)
-5.61%
Change (1 year)
Categories
Argenx is a Dutch company that develops antibody therapies to fight autoimmune diseases and cancer.
Argenx (ARGX) - Cash on Hand
Cash on Hand as of December 2023 : $3.17 B
According to Argenx
's latest financial reports the company has $3.17 B in cash and cash equivalents.
A company’s cash on hand also refered as cash/cash equivalents (CCE) and Short-term investments, is the amount of accessible money a business has.
Argenx - Cash on Hand chart (from 2021 to 2020)
Cash on Hand by year
| Year | Cash on Hand | Change |
|---|---|---|
| 2022-12-31 | $2.19 B | -6.17% |
| 2021-12-31 | $2.33 B | -4.84% |
| 2020-12-31 | $2.45 B | 46.07% |
| 2019-12-31 | $1.68 B | 127.54% |
| 2018-12-31 | $0.73 B | 42.58% |
| 2017-12-31 | $0.51 B | 383.85% |
| 2016-12-31 | $0.10 B | 111.65% |
| 2015-12-31 | $50.59 M | -38.88% |
| 2014-12-31 | $82.77 M | 86.94% |
| 2013-12-31 | $44.28 M | 53.59% |
| 2012-12-31 | $28.82 M | -27.1% |
| 2011-12-31 | $39.54 M | 183.14% |
| 2010-12-31 | $13.96 M |